Journal ArticleDOI
Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis
Thomas B. Casale,William W. Busse,Joel N. Kline,Zuhair K. Ballas,Mark H. Moss,Robert G. Townley,Masoud Mokhtarani,Vicki Seyfert-Margolis,Adam Asare,Kirk Bateman,Yamo Deniz +10 more
Reads0
Chats0
TLDR
Omalizumab pretreatment enhances the safety of RIT for ragweed allergic rhinitis and may be an effective strategy to permit more rapid and higher doses of allergen immunotherapy to be given more safely and with greater efficacy to patients with allergic diseases.Abstract:
Background Rush immunotherapy (RIT) presents an attractive alternative to standard immunotherapy. However, RIT carries a much greater risk of acute allergic reactions, including anaphylaxis. Objectives We hypothesized that omalizumab, a humanized monoclonal anti-IgE antibody, would be effective in enhancing both safety and efficacy of RIT. Methods Adult patients with ragweed allergic rhinitis were enrolled in a 3-center, 4-arm, double-blind, parallel-group, placebo-controlled trial. Patients received either 9 weeks of omalizumab (0.016 mg/kg/IgE [IU/mL]/mo) or placebo, followed by 1-day rush (maximal dose 1.2-4.0 μg Amb a 1) or placebo immunotherapy, then 12 weeks of omalizumab or placebo plus immunotherapy. Results Of the 159 patients enrolled, 123 completed all treatments. Ragweed-specific IgG levels increased >11-fold in immunotherapy patients, and free IgE levels declined >10-fold in omalizumab patients. Patients receiving omalizumab plus immunotherapy had fewer adverse events than those receiving immunotherapy alone. Post hoc analysis of groups receiving immunotherapy demonstrated that addition of omalizumab resulted in a 5-fold decrease in risk of anaphylaxis caused by RIT (odds ratio, 0.17; P = .026). On an intent-to-treat basis, patients receiving both omalizumab and immunotherapy showed a significant improvement in severity scores during the ragweed season compared with those receiving immunotherapy alone (0.69 vs 0.86; P = .044). Conclusion Omalizumab pretreatment enhances the safety of RIT for ragweed allergic rhinitis. Furthermore, combined therapy with omalizumab and allergen immunotherapy may be an effective strategy to permit more rapid and higher doses of allergen immunotherapy to be given more safely and with greater efficacy to patients with allergic diseases.read more
Citations
More filters
Journal ArticleDOI
Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)
Jean Bousquet,N. Khaltaev,Alvaro A. Cruz,Judah A. Denburg,W. J. Fokkens,Alkis Togias,T. Zuberbier,Carlos E. Baena-Cagnani,Giorgio Walter Canonica,C. van Weel,Ioana Agache,Nadia Aït-Khaled,Claus Bachert,Michael S. Blaiss,Sergio Bonini,L.-P. Boulet,Philippe-Jean Bousquet,Paulo Augusto Moreira Camargos,K-H. Carlsen,Y. Z. Chen,Adnan Custovic,Ronald Dahl,Pascal Demoly,H. Douagui,Stephen R. Durham,R. Gerth van Wijk,O. Kalayci,Michael A. Kaliner,You Young Kim,Marek L. Kowalski,Piotr Kuna,L. T. T. Le,Catherine Lemière,Jing Li,Richard F. Lockey,S. Mavale-Manuel,Eli O. Meltzer,Y. Mohammad,J Mullol,Robert M. Naclerio,Robyn E O'Hehir,K. Ohta,S. Ouedraogo,S. Palkonen,Nikolaos G. Papadopoulos,Gianni Passalacqua,Ruby Pawankar,Todor A. Popov,Klaus F. Rabe,J Rosado-Pinto,G. K. Scadding,F. E. R. Simons,Elina Toskala,E. Valovirta,P. Van Cauwenberge,De Yun Wang,Magnus Wickman,Barbara P. Yawn,Arzu Yorgancioglu,Osman M. Yusuf,H. J. Zar,Isabella Annesi-Maesano,E.D. Bateman,A. Ben Kheder,Daniel A. Boakye,J. Bouchard,Peter Burney,William W. Busse,Moira Chan-Yeung,Niels H. Chavannes,A.G. Chuchalin,William K. Dolen,R. Emuzyte,Lawrence Grouse,Marc Humbert,C. M. Jackson,Sebastian L. Johnston,Paul K. Keith,James P. Kemp,J. M. Klossek,Désirée Larenas-Linnemann,Brian J. Lipworth,Jean-Luc Malo,Gailen D. Marshall,Charles K. Naspitz,K. Nekam,Bodo Niggemann,Ewa Nizankowska-Mogilnicka,Yoshitaka Okamoto,M. P. Orru,Paul Potter,David Price,Stuart W. Stoloff,Olivier Vandenplas,Giovanni Viegi,Dennis M. Williams +95 more
TL;DR: The ARIA guidelines for the management of allergic rhinitis and asthma are similar in both the 1999 ARIA workshop report and the 2008 Update as discussed by the authors, but the GRADE approach is not yet available.
Journal ArticleDOI
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision
Jan Brozek,Jean Bousquet,Carlos E. Baena-Cagnani,Sergio Bonini,G. Walter Canonica,Thomas B. Casale,Roy Gerth van Wijk,Ken Ohta,Torsten Zuberbier,Holger J. Schünemann +9 more
TL;DR: These are the most recent and currently the most systematically and transparently developed recommendations about the treatment of allergic rhinitis in adults and children and patients are encouraged to use these recommendations in their daily practice and to support their decisions.
Journal ArticleDOI
Allergen immunotherapy: A practice parameter third update
Linda Cox,Harold S. Nelson,Richard F. Lockey,Christopher W. Calabria,Thomas Chacko,Ira Finegold,M.R. Nelson,Richard W. Weber,David I. Bernstein,Joann Blessing-Moore,David A. Khan,David M. Lang,Richard A. Nicklas,John Oppenheimer,Jay M. Portnoy,Christopher Randolph,Diane E. Schuller,Sheldon L. Spector,Stephen A. Tilles,Dana Wallace +19 more
TL;DR: These parameters were developed by the Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American Col- lege of Allergen,Asthma & immunology (ACAAI); and the Joint Council of All allergy, asthma, and Immunology.
Journal ArticleDOI
Mechanisms of allergen-specific immunotherapy
Cezmi A. Akdis,Mübeccel Akdis +1 more
TL;DR: The mechanisms of action of allergen-specific immunotherapy include the very early desensitization effects, modulation of T-and B-cell responses and related antibody isotypes, and migration of eosinophil, basophils, and mast cells to tissues, as well as release of their mediators.
Journal ArticleDOI
ImmPort: disseminating data to the public for the future of immunology
Sanchita Bhattacharya,Sandra Andorf,Linda Gomes,Patrick Dunn,Henry Schaefer,Joan Pontius,Patty Berger,Vince Desborough,Thomas Smith,John D.M. Campbell,Elizabeth Thomson,Ruth Monteiro,Patricia Guimaraes,Bryan Walters,Jeffrey Wiser,Atul J. Butte,Atul J. Butte +16 more
TL;DR: The immunology database and analysis portal (ImmPort) system is the archival repository and dissemination vehicle for clinical and molecular datasets created by research consortia funded by the National Institute of Allergy and Infectious Diseases Division of All allergy, Immunology, and Transplantation.
References
More filters
Journal ArticleDOI
Long-Term Clinical Efficacy of Grass-Pollen Immunotherapy
Stephen R. Durham,Samantha Walker,Eva-Maria Varga,Mikila R. Jacobson,Fiona O’Brien,Wendy Noble,Stephen J. Till,Qutayba Hamid,Kayhan T. Nouri-Aria +8 more
TL;DR: Althoughthere was a tendency for immediate sensitivity to allergen to return late after discontinuation, there was a sustained reduction in the late skin response and associated CD3+ T-cell infiltration and interleukin-4 messenger RNA expression.
Journal ArticleDOI
Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study).
Christian Möller,S. Dreborg,Hosne Ara Ferdousi,S. Halken,A Høst,Lars Jacobsen,A. Koivikko,Dieter Y. Koller,Bodo Niggemann,L A Norberg,Radvan Urbanek,Erkka Valovirta,Ulrich Wahn +12 more
TL;DR: In this article, the authors investigated whether specific immunotherapy can prevent the development of asthma and reduce bronchial hyperresponsiveness in children with seasonal allergic rhinoconjunctivitis.
Journal ArticleDOI
Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children.
TL;DR: A prospective non-randomized study was carried out in a population of asthmatic children younger than 6 years of age whose only allergic sensitivity was to house dust mites (HDMs) as discussed by the authors.
Journal ArticleDOI
Grass Pollen Immunotherapy Induces Mucosal and Peripheral IL-10 Responses and Blocking IgG Activity
Kayhan T. Nouri-Aria,Petra A. Wachholz,J.N. Francis,Mikila R. Jacobson,Samantha Walker,Louisa K. Wilcock,Steven Q. Staple,R. C. Aalberse,Stephen J. Till,Stephen R. Durham +9 more
TL;DR: Grass pollen immunotherapy may induce allergen-specific, IL-10-dependent “protective” IgG4 responses and both the increases in IgG and the IgG “blocking” activity correlated with the patients’ overall assessment of improvement.
Journal ArticleDOI
Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001.
TL;DR: A survey of fatal reactions related to skin testing and immunotherapy and of near-fatal immunotherapy reactions that transpired from 1990 through 2001 was conducted among member practices of the American Academy of Allergy, Asthma and Immunology.